Therapy for polycystic kidney disease? It's water, stupid!

Journal of the American Society of Nephrology

Volumn 19, Issue 1, 2008, Pages 1-2

  Grantham, Jared J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENYLATE CYCLASE; ADENYLATE CYCLASE AGONIST; ADRENALIN; CYCLIC AMP; FORSKOLIN; MOZAVAPTAN; NORADRENALIN; PARATHYROID HORMONE; PROSTAGLANDIN E2; SECRETIN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST; WATER;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; EDITORIAL; HUMAN; KIDNEY POLYCYSTIC DISEASE; MOLECULAR GENETICS; PRIORITY JOURNAL;

EID: 38149039935     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007101100     Document Type: Editorial

References (11)

1. Grantham JJ. 1992 Homer Smith Award: Fluid secretion, cellular proliferation, and the pathogenesis of renal epithelial cysts. J Am Soc Nephrol 3: 1841-1857, 1993
2. Torres VE: Cyclic AMP, at the hub of the cystic cycle. Kidney Int 66: 1283-1285, 2004
3. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ: Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964-973, 2004
4. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG: Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24: 309-318, 1999
5. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
6. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004
7. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005
8. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006
9. Wang W, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008
10. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ: Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003
11. Reif GA, Yamaguchi T, Mori T, Fujiki H, Grantham JJ, Wallace DP: Tolvaptan inhibits the MEK/ERK signaling pathway and proliferation of human ADPKD cyst epithelial cells in response to AVP [Abstract]. J Am Soc Nephrol 18: 368A, 2007